Group 1 - The core viewpoint of the articles highlights the strengthening of economic and technological cooperation between Vietnam and South Korea, particularly following the elevation of their relationship to a comprehensive strategic partnership in 2022 [1][2] - The bilateral trade volume reached $57.7 billion in the first eight months of 2025, marking a 7.3% year-on-year increase, with South Korea being Vietnam's third-largest trade partner [1] - South Korea remains the leading investor in Vietnam with approximately $94.2 billion in registered capital across 10,301 effective projects as of September 2025 [1] Group 2 - Both countries agreed to enhance collaboration in sectors such as semiconductors, AI, and renewable energy, and to establish joint R&D plans and technology transfer initiatives [2] - From 2026 to 2030, priority projects will focus on transportation infrastructure, urban development, and high-tech infrastructure, with an emphasis on sharing experiences and information [2] - Vietnam aims to leverage South Korea's expertise in infrastructure and high-tech manufacturing to support its goal of becoming a high-income developed country by 2045 [2]

人力资源社会保障部近日印发通知，确定了北京、天津、唐山等39个人力资源服务业与制造业融 合发展试点城市。这些城市有何特点？开展试点的重点任务是什么？记者采访了人力资源社会保障部人 力资源流动管理司负责人。 人力资源服务业作为现代生产性服务业重要门类，发挥着促进高质量充分就业、加强人力资源开发 利用、助力现代化产业体系建设的积极作用。 近年来，我国人力资源服务业实现长足发展。截至2024年底，全国各类人力资源服务机构7.4万 家，从业人员109万人。"十四五"时期，全行业年均为3亿人次劳动者提供就业、择业和流动服务，为 5000余万家次用人单位提供专业支持。在服务制造业等实体经济过程中，形成了一批适应制造企业招 聘用工需求的人力资源服务产品、模式和解决方案。 据介绍，试点城市基本覆盖我国经济大市和制造业重点区域，普遍具备较大规模的制造业特别是先 进制造业集群、比较发达的人力资源服务业基础、丰富的教育人才资源、较强的区域示范带动作用等条 件。 上述负责人说，试点城市制造业年产值规模体量大、吸纳就业能力强，是所在省份制造业发展较快 或代表性较强的城市，产业领域涉及智能制造等重点领域，招聘用人需求旺盛。同时，人力资源 ...

近年来，我国人力资源服务业实现长足发展。截至2024年底，全国各类人力资源服务机构7.4万家，从 业人员109万人。"十四五"时期，全行业年均为3亿人次劳动者提供就业、择业和流动服务，为5000余万 家次用人单位提供专业支持。在服务制造业等实体经济过程中，形成了一批适应制造企业招聘用工需求 的人力资源服务产品、模式和解决方案。 "试点城市将聚焦智能制造、电子信息、新材料、新能源、生物技术等制造业重点领域，差异化探索产 业升级与就业促进高效协同的创新路径，助力破解制约制造业发展的人力资源要素供给短板，提升制造 业人力资源开发利用水平。"上述负责人说。 新华财经北京11月14日电（记者张晓洁）人力资源社会保障部近日印发通知，确定了北京、天津、唐山 等39个人力资源服务业与制造业融合发展试点城市。这些城市有何特点？开展试点的重点任务是什么？ 记者采访了人力资源社会保障部人力资源流动管理司负责人。 试点城市将聚焦制造业重点领域，结合当地产业基础、资源禀赋和特色优势，确定1到3个细分行业作为 试点方向，开展差异化探索。充分发挥企业主体作用，重点选择制造业链主企业、制造业单项冠军企 业、专精特新中小企业和人力资源服务骨干 ...

Financial Data and Key Metrics Changes - The company ended Q3 2025 with a cash balance of $14.3 million and raised an additional $1.2 million since the quarter end, providing a runway through 2026 [23] - The net loss for Q3 2025 was $2.9 million, or $0.65 per share, compared to a net loss of $1.8 million, or $0.46 per share, for Q3 2024 [23] - For the nine months ended September 30, 2025, the net loss was $9.9 million, or $2.39 per share, compared to $8.3 million, or $2.24 per share for the same period in 2024 [23] Business Line Data and Key Metrics Changes - The ongoing trial of agenT-797, an allo off-the-shelf iNKT cell therapy, showed a median overall survival of approximately 23 months in patients with relapsed or refractory solid tumors when combined with PD-1 therapies [4] - Observations included complete remission in a patient with metastatic testicular cancer and durable partial responses in other difficult-to-treat cancers, demonstrating the potential of agenT-797 to restore immune function [5][6] Market Data and Key Metrics Changes - The company has established a strategic partnership with the University of Wisconsin Carbone Cancer Center to advance the iNKT program in immune reconstitution following stem cell transplantation [10] - The company is preparing for a global phase II trial in acute pulmonary dysfunction with multi-drug resistant infections, targeting a patient demographic that mirrors U.S. demographics [12] Company Strategy and Development Direction - MiNK Therapeutics is focused on advancing its iNKT Cell Therapy platform and has become the most clinically advanced company in developing allogeneic iNKT cells [8] - The company aims to redefine immune recovery in various conditions, including cancer, infection, critical illness, and transplantation, through innovative partnerships and disciplined capital use [9][22] Management's Comments on Operating Environment and Future Outlook - Management highlighted the importance of building public-private partnerships and emphasized the potential of iNKT cells to transform treatment in critical illness and transplantation [9][22] - The company expects to have multiple clinical programs actively enrolling patients by this time next year, with early readouts emerging from GVHD and pulmonary cohorts [28] Other Important Information - The company executed an at-the-market sales agreement, leveraging a significant increase in equity price to access cash while limiting dilution to shareholders [26] - The leadership team has been strengthened with the onboarding of Dr. John Holcomb and Dr. Therese Hammond, enhancing the company's clinical and operational capabilities [25] Q&A Session Summary Question: Expansion of the combination therapy cohort - Management indicated plans to expand the cohort for the combination therapy with PD-1, with a focus on patients who have failed prior PD-1 therapy, and will announce an expanded cohort moving into a phase two study [33][34] Question: Timing for the severe pulmonary disease trial - The company is in the activation phase and aims to dose the first patient by early next year, with efforts to initiate patient enrollment imminently [38] Question: Details on GVHD and pulmonary inflammation trials - Management provided insights into the GVHD trial, emphasizing endpoints such as GVHD presence or absence and the potential for significant improvements in patient outcomes [44][46] - For the pulmonary disease trial, the primary endpoint will be 28-day mortality, with a focus on patients with severe pneumonia and hypoxemic respiratory failure [51]

Group 1 - The China Securities Regulatory Commission (CSRC) has published supplementary material requirements for 10 companies, including Yingpai Pharmaceutical, which is required to clarify the pricing basis for past capital increases and share transfers, and whether there have been any instances of shareholding representation since its establishment [1] - Yingpai Pharmaceutical submitted its listing application to the Hong Kong Stock Exchange on September 26, with Goldman Sachs and CICC as joint sponsors [1] - The CSRC has requested legal opinions on the compliance of the company's past equity changes, including whether there are any unfulfilled capital contributions or irregularities in the contribution methods [1][2] Group 2 - Yingpai Pharmaceutical, established in 2009, is a biotechnology company focused on the global development of precision cancer therapies based on synthetic lethality mechanisms [2] - The company has developed a comprehensive and advanced synthetic lethality product portfolio and is one of only three companies globally with both commercial-stage PARP1/2 inhibitors and clinical-stage next-generation PARP1 selective inhibitors [2] - The core product, Senaparib, is a PARP1/2 inhibitor approved in China for first-line maintenance treatment of ovarian cancer in January 2025, showing the greatest progression-free survival benefit among approved PARP inhibitors for this indication [2]

Core Viewpoint - The China Securities Regulatory Commission (CSRC) has published supplementary material requirements for overseas listing applications, specifically addressing Nanjing Inpai Pharmaceutical Co., Ltd. and its compliance with various regulatory aspects [1][2]. Group 1: Regulatory Requirements - The CSRC has requested Inpai Pharmaceutical to clarify the pricing basis for its past capital increases and equity transfers, and to confirm whether there have been any violations regarding capital contributions or shareholding legality [1] - The company is also required to provide details on the compliance of its three overseas subsidiaries with foreign investment and foreign exchange registration regulations [1] - Additionally, the CSRC seeks confirmation on whether there have been any instances of shareholding representation since the company's establishment [1] Group 2: Shareholder Compliance - The company must disclose whether any shareholders holding more than 5% of shares have any domestic entities that are prohibited from holding shares under relevant laws and regulations [1] Group 3: Business Operations and Compliance - Inpai Pharmaceutical is required to explain its business scope and operations in relation to human stem cells, gene diagnosis, and treatment technologies, ensuring compliance with foreign investment policies [2] - The company must also confirm that its proposed issuance plan aligns with the regulatory guidelines for overseas listings and clarify the status of shares held by shareholders participating in the "full circulation" [2] Group 4: Company Overview - Inpai Pharmaceutical, established in 2009, is a biotechnology company focused on the global development of precision cancer therapies based on synthetic lethality mechanisms [2] - The company has developed a comprehensive and advanced portfolio of synthetic lethality products and is one of only three companies globally with both commercialized PARP1/2 inhibitors and clinical-stage next-generation PARP1 selective inhibitors [2] - Its core product, Senaparib, is a PARP1/2 inhibitor approved in January 2025 for first-line maintenance treatment of ovarian cancer in China, demonstrating the greatest progression-free survival benefit among approved PARP inhibitors for this indication [2]

Group 1: Funding Highlights in the Medical Sector - LambdaVision completed a $7 million angel round financing, with investments from Aurelia Foundry, Seraphim Space, and Seven Seven Six. The company is based in the USA and focuses on developing artificial retinas [1] - CustoMED secured $6 million in seed funding, with participation from Emerging Longevity Ventures, FLAG Capital Management, Longevity Venture Partners, Varana Capital, and the Israeli Innovation Authority. CustoMED is located in Israel and specializes in personalized and precision surgical technologies [1] - Microbio completed an angel round financing exceeding 100 million RMB, led by Qiming Venture Partners. The company is based in Shanghai and is an innovator in the in vivo cell therapy field, focusing on CAR-T therapies for hematological malignancies and autoimmune diseases [1] Group 2: Notable Financing Events - Zijing Zhikang raised nearly 100 million RMB in angel round financing, led by Xinglian Capital, with participation from Inno Angel Fund and Shangshi Capital. The company is located in Wuxi and develops medical intelligent algorithms [2] - Zhiyuan Shilan completed tens of millions in angel round financing, led by Woyan Capital, with continued support from existing investors. The company is based in Beijing and focuses on data-driven biomolecular design and manufacturing [2] - Azalea Tx raised a total of $82 million in seed and Series A financing, with participation from RA Capital Management, Sozo Ventures, Third Rock Ventures, and Yosemite. The company is based in the USA and specializes in precision genome editing technologies [2] Group 3: Advanced Medical Technologies - Curve Biosciences completed a $40 million Series A financing led by Luma Group. The company is based in the USA and offers a comprehensive smart platform for chronic disease monitoring [3] - Xiyuan Anjian raised over 200 million RMB in Series A financing, with investments from multiple venture capital firms. The company is located in Beijing and focuses on developing innovative biopharmaceuticals for tumors and chronic diseases [3] - AAVantgarde Bio secured $141 million in Series B financing, with participation from several prominent investment firms. The company is based in Italy and specializes in treatments for hereditary eye diseases [3] Group 4: Robotics and Innovative Drug Development - Agile Medical completed several hundred million RMB in Series B financing, led by Mingxi Capital. The company is based in Suzhou and specializes in surgical robotics [4] - Sovato raised Series B financing from multiple well-known investment institutions. The company is based in the USA and focuses on global remote robotic surgery services [4] - Yangli Pharmaceutical completed a significant Series B financing, exclusively led by Qiming Venture Partners. The company is located in Hangzhou and is engaged in innovative drug development [4] Group 5: Strategic Investments in Medical Innovations - Quanzhen Medical completed 100 million RMB in Series B financing, including a strategic round from an A-share listed company and additional funding from Good Doctor Group. The company is based in Hangzhou and focuses on medical large model innovations [5] - Andao Pharmaceutical raised over 400 million RMB in Series C financing, with investments from various funds and institutions. The company is located in Hangzhou and specializes in new drug development for kidney diseases, anemia, and cancer [5]

Core Viewpoint - The Hong Kong stock market has seen significant gains in certain biotechnology stocks, with notable increases in share prices for several companies on November 14. Group 1: Stock Performance - The newly listed company 旺山旺水 has surged over 25%, leading the gains in the biotechnology sector [1] - 圣诺医药 has experienced an increase of over 17% [1] - 基石药业 has risen nearly 17% [1] - 劲方医药 has seen an increase of over 8% [1]

登录新浪财经APP 搜索【信披】查看更多考评等级 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容 的真实性、准确性和完整性依法承担法律责任。 重要内容提示： ●会议召开时间：2025年11月20日（星期四） 16:00-17:00 ●会议召开地点：上海证券交易所上证路演中心（网址：https://roadshow.sseinfo.com/） ●会议召开方式：上证路演中心网络互动 ●会议问题征集：投资者可于2025年11月19日(星期三)16:00前登录上证路演中心网站首页点击"提问预征 集"栏目或通过公司邮箱bo@innostarbio.com进行会前提问，公司将在本次说明会上对投资者普遍关注的 问题进行回答。 本次投资者说明会以网络互动形式召开，公司将针对2025年第三季度的经营成果及财务指标的具体情况 与投资者进行互动交流和沟通，在信息披露允许的范围内就投资者普遍关注的问题进行回答。 二、说明会召开的时间、地点 董事会秘书：李燕女士 独立董事：范国钦先生 （如有特殊情况，参会人员可能进行调整） 四、投资者参加方式 （一）投资者可在2025年11月20日（星期四） ...

Summary of Abeona Therapeutics Conference Call Company Overview - **Company**: Abeona Therapeutics (NasdaqCM:ABEO) - **Industry**: Biotechnology, specifically focused on cell and gene therapy - **Product**: ZivaSkin, approved for treating recessive dystrophic epidermolysis bullosa (RDEB) [2][80] Key Points and Arguments Product Launch and Demand - ZivaSkin was approved in Q2 2025, and the company is making significant progress towards its U.S. launch [2][80] - Patient demand is strong, with favorable coverage from payers and interest from Centers of Excellence (QTCs) [2][80] - The company has received 12 ZivaSkin Product Order Forms (ZPOFs) from identified patients, indicating a good conversion rate [28][29] Manufacturing and Sterility Testing - A temporary pause was placed on patient biopsy collection to optimize a sterility test after a false positive was detected during the first manufacturing run [3][4] - The FDA required a more robust sterility testing process, which has now been validated, reducing the risk of false positives from 35% to less than 1% [19][20] - The shelf life of the manufactured product is 84 hours, necessitating careful scheduling of surgeries [13][20] Patient Treatment and Logistics - The company is working to schedule surgeries within a tight timeframe, with a focus on maximizing patient logistics [23][24] - The average time from patient identification to treatment is expected to decrease from 3-4 months to 2-3 months as payer policies improve [31][32] Expansion of Treatment Centers - Abeona aims to activate 5-7 QTCs by 2026, with ongoing discussions with hospitals interested in becoming treatment centers [46][47] - The company is strategically considering geographic locations to ensure broad access for patients [47] Reimbursement and Coverage - A permanent J Code has been received, which is expected to streamline the reimbursement process for hospitals [58][60] - The payer mix shows that 60% of patients are commercially insured, with baseline coverage established for all 50 states [59][60] Future Growth and Capacity - The company plans to increase manufacturing capacity from 6 to 10 slots per month by mid-2026, with potential for further expansion [72][73] - The total addressable market (TAM) is estimated at 750 patients, with an expectation that each patient may require an average of two treatments [75][76] Pipeline and Financial Outlook - Abeona has a gene therapy platform with ongoing preclinical assets, including ABO 503, which has been selected for a rare disease pilot program by the FDA [78][79] - The company reported $207.5 million in cash, providing a two-year operating runway, with expectations to become profit-generating in the first half of 2026 [80] Additional Important Information - The company is focused on building relationships with Centers of Excellence to enhance patient access and treatment options [54][55] - There is a positive outlook on the competitive landscape, as ZivaSkin is an approved product, which may favor its utilization over investigational products [54][56]